{"name": "Juventas Therapeutics",
 "permalink": "juventas-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/juventas-therapeutics",
 "homepage_url": "http://www.juventasinc.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2007,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@juventasinc.com",
 "phone_number": "",
 "description": "",
 "created_at": "Thu Apr 28 02:11:11 UTC 2011",
 "updated_at": "Wed Apr 17 13:53:24 UTC 2013",
 "overview": "\u003Cp\u003EJuventas Therapeutics, headquartered in Cleveland, OH, is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life\u00e2\u20ac\u201cthreatening diseases. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials. Investors include Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received nondilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell \u0026amp; Regenerative Medicine.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       66],
      "assets/images/resized/0013/2328/132328v1-max-150x150.jpg"],
     [[196,
       87],
      "assets/images/resized/0013/2328/132328v1-max-250x250.jpg"],
     [[196,
       87],
      "assets/images/resized/0013/2328/132328v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman",
    "person":
     {"first_name": "George",
      "last_name": "Emont",
      "permalink": "george-emont",
      "image":
       {"available_sizes":
         [[[121,
            150],
           "assets/images/resized/0025/2390/252390v2-max-150x150.jpg"],
          [[121,
            150],
           "assets/images/resized/0025/2390/252390v2-max-250x250.jpg"],
          [[121,
            150],
           "assets/images/resized/0025/2390/252390v2-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Rahul",
      "last_name": "Aras",
      "permalink": "rahul-aras",
      "image":
       {"available_sizes":
         [[[119,
            150],
           "assets/images/resized/0025/2279/252279v1-max-150x150.jpg"],
          [[120,
            151],
           "assets/images/resized/0025/2279/252279v1-max-250x250.jpg"],
          [[120,
            151],
           "assets/images/resized/0025/2279/252279v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Vice President, Product Development",
    "person":
     {"first_name": "Joseph",
      "last_name": "Pastore",
      "permalink": "joseph-pastore",
      "image":
       {"available_sizes":
         [[[115,
            143],
           "assets/images/resized/0025/2385/252385v1-max-150x150.jpg"],
          [[115,
            143],
           "assets/images/resized/0025/2385/252385v1-max-250x250.jpg"],
          [[115,
            143],
           "assets/images/resized/0025/2385/252385v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "George",
      "last_name": "Arida",
      "permalink": "george-arida",
      "image":
       {"available_sizes":
         [[[119,
            150],
           "assets/images/resized/0025/2393/252393v1-max-150x150.jpg"],
          [[120,
            151],
           "assets/images/resized/0025/2393/252393v1-max-250x250.jpg"],
          [[120,
            151],
           "assets/images/resized/0025/2393/252393v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Matthew",
      "last_name": "Pollman",
      "permalink": "matthew-pollman",
      "image":
       {"available_sizes":
         [[[121,
            150],
           "assets/images/resized/0025/2406/252406v1-max-150x150.jpg"],
          [[121,
            150],
           "assets/images/resized/0025/2406/252406v1-max-250x250.jpg"],
          [[121,
            150],
           "assets/images/resized/0025/2406/252406v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Roger",
      "last_name": "Newton",
      "permalink": "roger-newton",
      "image":
       {"available_sizes":
         [[[121,
            150],
           "assets/images/resized/0025/2405/252405v1-max-150x150.jpg"],
          [[121,
            150],
           "assets/images/resized/0025/2405/252405v1-max-250x250.jpg"],
          [[121,
            150],
           "assets/images/resized/0025/2405/252405v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Linda",
      "last_name": "Tufts",
      "permalink": "linda-tufts",
      "image":
       {"available_sizes":
         [[[121,
            150],
           "assets/images/resized/0025/2408/252408v1-max-150x150.jpg"],
          [[121,
            150],
           "assets/images/resized/0025/2408/252408v1-max-250x250.jpg"],
          [[121,
            150],
           "assets/images/resized/0025/2408/252408v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Senior Director, Research and Development",
    "person":
     {"first_name": "Joseph",
      "last_name": "Pastore",
      "permalink": "joseph-pastore",
      "image":
       {"available_sizes":
         [[[115,
            143],
           "assets/images/resized/0025/2385/252385v1-max-150x150.jpg"],
          [[115,
            143],
           "assets/images/resized/0025/2385/252385v1-max-250x250.jpg"],
          [[115,
            143],
           "assets/images/resized/0025/2385/252385v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Director, Product Development",
    "person":
     {"first_name": "Joseph",
      "last_name": "Pastore",
      "permalink": "joseph-pastore",
      "image":
       {"available_sizes":
         [[[115,
            143],
           "assets/images/resized/0025/2385/252385v1-max-150x150.jpg"],
          [[115,
            143],
           "assets/images/resized/0025/2385/252385v1-max-250x250.jpg"],
          [[115,
            143],
           "assets/images/resized/0025/2385/252385v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$22.2M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.finsmes.com/2012/07/juventas-therapeutics-closes-22-2m-series-financing.html?utm_source=feedburner\u0026utm_medium=feed\u0026utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29",
    "source_description": "Juventas Therapeutics Closes $22.2M Series B Financing",
    "raised_amount": 22200000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 7,
    "funded_day": 16,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Triathlon Medical Venture Partners",
         "permalink": "triathlon-medical-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               49],
              "assets/images/resized/0004/5663/45663v2-max-150x150.png"],
             [[200,
               66],
              "assets/images/resized/0004/5663/45663v2-max-250x250.png"],
             [[200,
               66],
              "assets/images/resized/0004/5663/45663v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "New Science Ventures",
         "permalink": "new-science-ventures",
         "image":
          {"available_sizes":
            [[[150,
               88],
              "assets/images/resized/0004/2733/42733v2-max-150x150.png"],
             [[158,
               93],
              "assets/images/resized/0004/2733/42733v2-max-250x250.png"],
             [[158,
               93],
              "assets/images/resized/0004/2733/42733v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Fletcher Spaght Ventures",
         "permalink": "fletcher-spaght-ventures",
         "image":
          {"available_sizes":
            [[[150,
               22],
              "assets/images/resized/0010/2158/102158v2-max-150x150.png"],
             [[250,
               37],
              "assets/images/resized/0010/2158/102158v2-max-250x250.png"],
             [[370,
               55],
              "assets/images/resized/0010/2158/102158v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Reservoir Venture Partners",
         "permalink": "reservoir-venture-partners",
         "image":
          {"available_sizes":
            [[[141,
               100],
              "assets/images/resized/0005/8550/58550v2-max-150x150.jpg"],
             [[141,
               100],
              "assets/images/resized/0005/8550/58550v2-max-250x250.jpg"],
             [[141,
               100],
              "assets/images/resized/0005/8550/58550v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Early Stage Partners",
         "permalink": "early-stage-partners",
         "image":
          {"available_sizes":
            [[[123,
               86],
              "assets/images/resized/0004/6832/46832v1-max-150x150.jpg"],
             [[123,
               86],
              "assets/images/resized/0004/6832/46832v1-max-250x250.jpg"],
             [[123,
               86],
              "assets/images/resized/0004/6832/46832v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Takeda Ventures",
         "permalink": "takeda-ventures",
         "image":
          {"available_sizes":
            [[[150,
               53],
              "assets/images/resized/0023/2460/232460v2-max-150x150.png"],
             [[225,
               80],
              "assets/images/resized/0023/2460/232460v2-max-250x250.png"],
             [[225,
               80],
              "assets/images/resized/0023/2460/232460v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Venture Investors",
         "permalink": "venture-investors",
         "image":
          {"available_sizes":
            [[[150,
               40],
              "assets/images/resized/0006/2067/62067v1-max-150x150.jpg"],
             [[217,
               58],
              "assets/images/resized/0006/2067/62067v1-max-250x250.jpg"],
             [[217,
               58],
              "assets/images/resized/0006/2067/62067v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "HQ",
    "address1": "3615 Superior Avenue, ",
    "address2": "Suite 4403C",
    "zip_code": "44114",
    "city": "Cleveland",
    "state_code": "OH",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Juventas plans $25M venture round in wake of PhI success\r\n",
    "stoned_year": 2011,
    "stoned_month": 4,
    "stoned_day": 27,
    "source_url": "http://www.fiercebiotech.com/story/juventas-plans-25m-venture-round-wake-phi-success/2011-04-27?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Juventas plans $25M venture round in wake of PhI success",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Juventas Therapeutics",
      "permalink": "juventas-therapeutics"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}